Clinical trials of GLP-1 patches have consistently shown lower and more variable absorption compared to subcutaneous injections, meaning patients experience less predictable appetite suppression and metabolic effects
Who is behind this product
Anti-inflammatory effects of GLP-1 medicines independent of weight loss Several GLP-1 medicines, including semaglutide, liraglutide, and exenatide, reduce plasma levels of C-reactive protein (CRP), a surrogate of systemic inflammation, in people with obesity or T2D
Unlike semaglutide, which targets GLP-1 only, or tirzepatide (GLP-1 + GIP), Retatrutide adds glucagon receptor activity that increases resting energy expenditure, a mechanism not present in either predecessor
Always talk to a trusted healthcare professional about safe, effective options for weight loss and diabetes management
Therefore, a thorough clinical assessment is necessary before prescribing